T2D Might Increase Risk Of Post Colonoscopy Colorectal Cancer: BMC
- byDoctor News Daily Team
- 13 July, 2025
- 0 Comments
- 0 Mins
Post-colonoscopy colorectal cancer (PCCRC), a term endorsed by the World Endoscopy Organization, refers to colorectal cancers (CRCs) diagnosed after a negative colonoscopy with a prevalence of up to 8% of all colorectal cancers. A recent study suggests that patients with type 2 diabetes (T2D) have an increased relative risk of post-colonoscopy colorectal cancers compared with patients without T2D. The study findings were published in the journal BMJ Open Gastroenterology on December 24, 2021.
PAUSE
UNMUTE
:
FULLSCREEN
Studies have shown that patients with T2D are at particularly high risk of CRC. However, evidence regarding the impact of T2D on the risk of PCCRC is needed to improve the overall colonoscopy quality and to guide clinical decision making, particularly for planning surveillance colonoscopies for patients with T2D within CRC screening programmes. Therefore, Dr Frederikke Schønfeldt Troelsen and his team conducted a study to investigate whether patients with T2D are at increased risk of PCCRC compared with patients without T2D.
The researchers conducted a population-based cohort study of patients with T2D and without T2D undergoing colonoscopy in Denmark (1995–2015). Among 362263 patients undergoing colonoscopy, the researchers observed 250 PCCRCs among patients with T2D and 1658 PCCRCs among patients without T2D. They assessed the risk of PCCRC by calculating >6 to 36 months cumulative incidence proportions (CIPs) treating, death and colectomy as competing risks. They evaluated the HRs of PCCRC, comparing patients with T2D and non-T2D using Cox proportional-hazards regression analyses. According to the World Endoscopy Organization guidelines, they calculated PCCRC 3-year rates to estimate the proportions of T2D and non-T2D CRC patients experiencing PCCRC.
Key findings of the study:
Upon analysis, the researchers found that the CIP after a first-time colonoscopy was 0.64% or T2D and 0.36% for patients without T2D.
Compared with patients without T2D, they noted that those with T2D had elevated aHRs of PCCRC after the first colonoscopy (1.44) and second colonoscopy (1.18).
They observed that the PCCRC rates at 3 years were 7.9% for patients with T2D vs 7.4% without T2D.
The authors concluded, "We found that patients with T2D had an increased HR of PCCRC compared with patients without T2D. These findings could indicate that impaired quality of bowel preparation for colonoscopy among patients with T2D may increase the risk of overlooked precancerous polyps, thereby increasing the risk of PCCRC."
For further information:
DOI: 10.1136/bmjgast-2021-000786
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Eli Lilly plans to build new USD 3 billion facilit...
- 04 November, 2025
Rajkot Maternity Hospital CCTV Leak: How a simple...
- 04 November, 2025
Gland Pharma profit rises 12 percent to Rs 184 cro...
- 04 November, 2025
AIIMS Delhi doctors told to use Hindi in prescript...
- 04 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!